TP53 and neoplasm: The majority of the cohort (53/67 tumors; 80%) had loss of function (LoF) mutations in TP53. They were concordant between the primary tumor and recurrence(s) in all but one of the patients, when limited to alternative allele fraction (AAF) of ≥5%; several tumors had additional TP53 mutations at AAF < 5% (Fig. 1a; Supplementary Fig. 1a–c and Supplementary Data 3).